Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Lenvatinib
Related studies linked through entity extraction aliases.
STUPP Regimen With or Without Lenvatinib for Newly Diagnosed Glioblastoma With MGMT Promoter Methylation
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical Trial
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Becotatug Vedotin Plus Tislelizumab and Low-Dose Lenvatinib for Advanced Esophageal Squamous Cell Carcinoma, Phase II
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
HAIC + DEB-TACE + Toripalimab + Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Phase 2 Study of Pembrolizumab and Lenvatinib in Anal Squamous Cell Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Failure of First-Line Therapy With Platinum-based Doublet and Immunotherapy
- Status
- RECRUITING
- Phase
- PHASE2
Perioperative Trial With IO/TKI for Multi-stage Clear Cell Renal Cell Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
Efficacy and Safety Comparison Between PD-1 Inhibitor Combined With Lenvatinib or With Regorafenib For UHCC After Failure of First-line Treatment
- Status
- COMPLETED
- Phase
- NA
Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Lenvatinib or Regorafenib for Advanced Hepatocellular Carcinoma After Immunotherapy (REVIVE)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Fostrox Plus Lenvatinib vs Lenvatinib in Advanced Hepatocellular Carcinoma After First-line Immunotherapy
- Status
- RECRUITING
- Phase
- PHASE2
TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence
- Status
- RECRUITING
- Phase
- PHASE3
HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2